Use of amphpramone, femproporex, mazindol and sibutramin in the treatment of patients with overweight or obesity: pharmacological and clinical analysis
DOI:
https://doi.org/10.37497/ijhmreview.v6i2.210Keywords:
Overweight, Obesity, Amfepramone, Fenproporex, Mazindol, Sibutramine.Abstract
Obesity is a disorder of energy metabolism in which there is excessive triglyceride accumulation in adipose tissue. Today, there is increasing media appeal towards an ever-growing search for thinness. Thus, there is an increase in the use of anorexigens, also known as appetite suppressants, in an abusive and irrational manner, leading to the development of chronic diseases, such as type 2 diabetes mellitus, hypertension and cardiovascular diseases, besides causing severe adverse reactions, such as increased blood pressure, dry mouth, increased heart rate, insomnia, constipation, nervousness, among others. The main appetite suppressant drugs are: amfepramone, fenproporex, mazindol and sibutramine. The main objective of this article is to identify the main impacts on the cardiovascular system of the use of appetite suppressants. The present work is a theoretical research though bibliographic survey and search for on-topic articles. Searches will also be carried out in electronic databases. Conclusion: These drugs should be used with caution, as they present contraindications and serious side effects, and may even cause dependence.
Downloads
How to Cite
Issue
Section
License
Authors who publish in this journal agree to the following terms: The author(s) authorize the publication of the text in the journal; The author(s) guarantee that the contribution is original and unpublished and is not in the process of being evaluated by any other journal(s); The journal is not responsible for the opinions, ideas, and concepts contained in the texts, as these are the sole responsibility of their respective author(s); The editors reserve the right to make adjustments to the text in order to ensure that it adheres to the standards of the journal. Authors retain the copyrights and grant the journal the right of first publication, with the article simultaneously licensed under the Creative Commons Attribution License which allows the sharing of the article with the acknowledgment of authorship and initial publication in this journal. Authors are authorized to take additional contracts separately, for the non-exclusive distribution of the version of the article published in this journal (e.g. publication in an institutional repository or as a book chapter), with the acknowledgment of authorship and initial publication in this journal.
Authors are allowed and encouraged to publish and distribute their work online (e.g. in institutional repositories or on their personal webpage) at any point before or during the editorial process, as this can generate productive changes as well as increase the impact and citation of published work (See The Effect of Free Access at http://opcit.eprints.org/oacitation-biblio.html)
